Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from a combined analysis of SOFT-TEXT after a median follow-up of 13 years
Glofitamab induces durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma
FDA also approved the QIAGEN therascreen KRAS RGQ PCR kit (tissue) and the Agilent Resolution ctDx FIRST Assay (plasma) as companion diagnostics
Evidence for efficacy is based on the results from the Study ML39345
Findings from a randomised phase III study
Findings from a prespecified secondary analysis of the HOPE study
Findings from the KEYNOTE-394 study
It also approved the Abbott RealTime IDH1 Assay to select patients
Findings from an updated exploratory analysis of the HER2CLIMB study
Findings from an international randomised parallel group study
Findings from c-TRAK TN study
Application for extension of therapeutic indications concerned the use to treat patients from 12 years of age who have RET-mutated medullary thyroid cancer or RET fusion-positive thyroid cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
